Study authors conducted a retrospective cohort study to assess whether chronic immunosuppression worsens outcomes for patients hospitalized with COVID-19.
The randomized, placebo-controlled, observer-blind study is evaluating the safety, tolerability, and immunogenicity of BNT162b2 in approximately 4000 healthy pregnant women aged 18 years and older who are 24 to 34 weeks’ gestation.
In an interview with Christine Moutier, MD, psychiatrist and chief medical officer of the American Foundation for Suicide Prevention, she speaks about how the current COVID-19 pandemic presents opportunities to improve suicide prevention efforts on multiple levels.
Face masks will be mandatory at transportation hubs and on planes and all forms of public transportation under a US Centers for Disease Control and Prevention order.
Study authors conducted a systematic review and meta-analysis to assess the efficacy of Janus kinase-inhibitors and Type I interferons as potential antiviral candidates for the treatment of COVID-19.
For light sedation of mechanically ventilated adults with sepsis, outcomes do not differ significantly for those receiving dexmedetomidine or propofol.
Study authors assessed whether convalescent plasma with high SARS-CoV-2 antibody titers would prevent progression to severe disease in older patients with COVID-19 if administered within 72 hours after the onset of mild symptoms.
Study authors compared oral moxifloxacin with combined intravenous ertapenem followed by oral levofloxacin in the managed of uncomplicated acute appendicitis.
Study authors assessed whether prophylactic azithromycin can prevent worsening of lung function and reduce acute respiratory exacerbations in children with HCLD taking ART.
Study authors examined the risk for admission and respiratory failure in patients with rheumatic disorders with COVID-19 receiving DMARDs or methotrexate.
The approval of Cabenuva was based on data from two phase 3 trials which included 1182 HIV-infected adults who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) prior to initiation.